US 11,690,859 B2
Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
JoMay Chow, Westerville, OH (US); Steven R. Davis, Galena, OH (US); Rachael Buck, Gahanna, OH (US); Geralyn O. Duska-McEwen, Columbus, OH (US); and Hawley K. Linke, Columbus, OH (US)
Assigned to ABBOTT LABORATORIES, Abbott Park, IL (US)
Filed by ABBOTT LABORATORIES, Abbott Park, IL (US)
Filed on Nov. 27, 2019, as Appl. No. 16/698,422.
Application 15/401,488 is a division of application No. 13/334,933, filed on Dec. 22, 2011, granted, now 9,539,269, issued on Jan. 10, 2017.
Application 16/698,422 is a continuation of application No. 16/680,054, filed on Nov. 11, 2019, granted, now 11,179,406.
Application 16/680,054 is a continuation of application No. 15/401,488, filed on Jan. 9, 2017, granted, now 10,471,081, issued on Nov. 12, 2019.
Claims priority of provisional application 61/428,863, filed on Dec. 31, 2010.
Claims priority of provisional application 61/428,868, filed on Dec. 31, 2010.
Prior Publication US 2020/0093846 A1, Mar. 26, 2020
Int. Cl. A61K 31/70 (2006.01); A01N 43/04 (2006.01); A61K 31/702 (2006.01); A23L 33/00 (2016.01); A61K 31/716 (2006.01); A61K 45/06 (2006.01); A23L 33/10 (2016.01); A23L 33/12 (2016.01); A23L 33/19 (2016.01); A23L 33/135 (2016.01); A61K 9/107 (2006.01); A61K 31/733 (2006.01); A61K 35/20 (2006.01); A61K 35/744 (2015.01); A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61K 36/48 (2006.01); A61K 38/01 (2006.01); A61K 35/00 (2006.01)
CPC A61K 31/702 (2013.01) [A23L 33/10 (2016.08); A23L 33/12 (2016.08); A23L 33/135 (2016.08); A23L 33/19 (2016.08); A23L 33/30 (2016.08); A23L 33/40 (2016.08); A61K 9/107 (2013.01); A61K 31/716 (2013.01); A61K 31/733 (2013.01); A61K 35/20 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A61K 36/48 (2013.01); A61K 38/018 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01); A61K 2035/11 (2013.01); A61K 2035/115 (2013.01)] 16 Claims
 
1. A shelf stable synthetic formula for improving the feeding tolerance of an infant, toddler, or child, the synthetic formula comprising:
from about 0.04 mg/mL to about 20 mg/mL of a human milk oligosaccharide blend consisting of 2′-fucosyllactose, 3-fucosyllactose, 3′-sialyllactose, 6′-sialyllactose, and at least one of lacto-N-tetraose and lacto-N-neotetraose, wherein the oligosaccharide blend comprises 2′-fucosyllactose, in a concentration of from 0.01 mg/mL to 10 mg/mL, and 6′-sialyllactose, in a concentration of from 0.01 to 10 mg/mL;
from about 0.001 g/L to about 1 g/L of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid, wherein the ratio of docosahexaenoic acid to arachidonic acid is from about 1:4 to about 1:2;
from about 0.001 μg/mL to about 5 μg/mL of a carotenoid component comprising lutein, lycopene, beta-carotene, or a combination thereof;
from about 42 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
wherein from about 7% to about 40% of total calories in the formula are derived from protein, from about 25% to about 50% of total calories in the formula are derived from fat, and from about 35% to about 55% of total calories in the formula are derived from carbohydrates; and
wherein the synthetic formula is shelf stable for at least 3 months.